Hyperbaric oxygen therapy suppresses CD133 and ALDH1 expression in orally induced DMBA ovarian cancer rat models
Bali Medical Journal · 05.08.2026 · 15 (2) · 276-282
DOI: 10.15562/bmj.v15i2.5938 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bali Medical Journal, online erschienen am 05.08.2026. Verfasst von I Ketut Edy Sudiarta und 4 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Ovarian cancer is one of the leading causes of mortality among gynecological malignancies, with a five-year survival rate of approximately 45-50%. Disease progression, chemoresistance, and unfavorable prognosis have been associated with ovarian cancer stem cells (OCSCs), which are commonly identified by the expression of CD133 and ALDH1. Hypoxia within the tumor microenvironment promotes cancer stem cell characteristics, whereas hyperbaric oxygen therapy (HBOT) has the potential to improve tissue oxygenation and counteract hypoxia-related mechanisms. This study aims to determine the effect of HBOT on the expression of CD133 and ALDH1 in a DMBA-induced rat model of ovarian carcinogenesis.
Methods
This experimental study employed a sequential design using 30 female Wistar rats allocated into three groups: a control group, a DMBA-induced ovarian cancer group, and a DMBA-induced group receiving HBOT. Ovarian carcinogenesis was induced by oral administration of DMBA at 20 mg/kg body weight twice weekly for two weeks, followed by an 11-week tumor development period before HBOT administration. HBOT was administered with 100% oxygen at 1.7 ATA for three 30-minute sessions daily over five consecutive days. Following completion of HBOT, ovarian tissues were collected for histopathological and immunohistochemical analyses. CD133 and ALDH1 expression was quantified using the H-score based on staining intensity and the proportion of positive cells.
Results
HBOT significantly decreased the expression of both ovarian cancer stem cell markers in the DMBA-induced group. The mean CD133 H-score declined from 45.73 ± 17.51 before HBOT to 23.73 ± 7.90 after HBOT (p = 0.004), while the mean ALDH1 H-score decreased from 31.08 ± 11.99 to 13.70 ± 10.95 (p = 0.003). Histopathological examination showed neoplastic-like alterations in the DMBA-induced ovaries, whereas HBOT-treated animals exhibited partial restoration of tissue architecture with reduced cellular atypia. No statistically significant differences were observed between the control and post-HBOT groups for CD133 (p = 0.151) or ALDH1 (p = 0.229), showing that marker expression following HBOT was comparable to the baseline control condition.
Conclusion
HBOT significantly reduced the expression of CD133 and ALDH1 in a DMBA-induced rat model of ovarian carcinogenesis. The comparable expression levels between the post-HBOT and control groups suggest that HBOT may modulate ovarian cancer stem cell-related marker expression and partially restore these markers toward normal levels following DMBA-induced carcinogenesis. However, further mechanistic studies are required to determine whether these effects are mediated through changes in tumor hypoxia and related molecular pathways.
Zitieren
APA
Sudiarta, I. K. E., Husodo, S. Y., Destriani, N. P. I., Mulyadi, A., & Leksodimulyo, M. C. (2026). Hyperbaric oxygen therapy suppresses CD133 and ALDH1 expression in orally induced DMBA ovarian cancer rat models. Bali Medical Journal, 15(2), 276-282. https://doi.org/10.15562/bmj.v15i2.5938
Vancouver
Sudiarta IKE, Husodo SY, Destriani NPI, Mulyadi A, Leksodimulyo MC. Hyperbaric oxygen therapy suppresses CD133 and ALDH1 expression in orally induced DMBA ovarian cancer rat models. Bali Medical Journal. 2026;15(2):276-282. doi:10.15562/bmj.v15i2.5938
BibTeX
@article{Sudiarta2026,
author = {Sudiarta, I Ketut Edy and Husodo, Stella Yuanita and Destriani, Ni Putu Ita and Mulyadi, Angelina and Leksodimulyo, Marcella Clarineta},
title = {Hyperbaric oxygen therapy suppresses CD133 and ALDH1 expression in orally induced DMBA ovarian cancer rat models},
journal = {Bali Medical Journal},
year = {2026},
volume = {15},
number = {2},
pages = {276--282},
doi = {10.15562/bmj.v15i2.5938}
}
EUVIMED